表紙
市場調查報告書
商品編碼
796847

脊髓性肌萎縮症的全球市場:產業分析與未來展望

Global Spinal Muscular Atrophy Market: Industry Analysis & Outlook (2019-2026)

出版日期: | 出版商: Koncept Analytics | 英文 72 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球脊髓性肌萎縮症的相關市場相關分析,整體市場規模趨勢預測 (今後8年份) ,及各地區、各產品種類 (疾病的各類型)的詳細趨勢彙整,主要企業的簡介,企業間的業績指標比較分析等資訊,為您概述為以下內容。

第1章 市場概要

第2章 全球脊髓性肌萎縮症的市場

  • 市場規模的預測值 (以金額為準)
  • 市場規模的預測值 (以金額為準):AVXS-101遺傳基因療法
  • 市場規模的預測值 (以金額為準),各地區:AVXS-101遺傳基因療法
  • 市場規模的預測值 (以金額為準):SRK-015藥物
  • 市場規模的預測值 (以金額為準),各地區:SRK-015藥物
  • 脊髓性肌萎縮症的發病數量:各地區
  • 脊髓性肌萎縮症的患病人數:各地區

第3章 各地區的脊髓性肌萎縮症市場

  • 美國的AVXS-101遺傳基因療法市場:市場規模的預測值
  • 美國的AVXS-101遺傳基因療法市場:市場規模的預測值,疾病的各類型
    • 類型I
    • 類型II
  • 美國的SRK-015藥物市場:市場規模的預測值
  • 美國的SRK-015藥物市場:市場規模的預測值,疾病的各類型
  • 歐洲的AVXS-101遺傳基因療法市場:市場規模的預測值
  • 歐洲的AVXS-101遺傳基因療法市場:市場規模的預測值,疾病的各類型
  • 歐洲的SRK-015藥物市場:市場規模的預測值
  • 歐洲的SRK-015藥物市場:市場規模的預測值,疾病的各類型

第4章 市場動態

  • 市場成長促進因素
  • 主要趨勢和動靜
  • 課題

第5章 競爭環境

  • 主要企業的簡介 - 全球脊髓性肌萎縮症市場
    • 市場收益額:企業間比較
    • 藥物的功能:企業間比較
    • 股票市值:企業間比較

第6章 企業簡介

  • Biogen Inc.
    • 產業概要
    • 主要的財務指標
    • 事業策略
  • Novartis International AG
  • Roche Holding AG
  • Cytokinetics, Inc
目錄

Spinal Muscular Atrophy (SMA) is a form of neuromuscular disease that results in loss of lower motor neurons and progressive muscle wasting, often leading to early death. Presently, it affects about 1 in 11,000 babies and about 1 in every 50 Americans is the disease carrier. On the basis of either the onset age of symptoms, SMA is classified into Type I, Type II, Type III and Type IV diseases.

Currently, no specific therapies for cure exist, but certain speciality drugs are expected to enter the market in the year 2019. The clinical care differs with the severity or type of the disorder category.

The global market is expected to witness a lucrative growth due the rising pharmaceuticals research and development (R&D) expenditures, increasing personal healthcare expenditure, accelerating economic growth and growing spinal muscular atrophy occurrence. The market is trending with progressing drug pipeline and high preference for gene therapy. However, there are some growth hindering factors in the market including lethargic drug approval process and associated business risks.

Regionally, the U.S. is expected to hold the leading position in the market, due to the increasing prevalence of motor neuron disorders in the population along with high preference of genetic correction therapy and myostatin drugs.

"Global Spinal Muscular Atrophy Market: Industry Analysis & Outlook (2019-2026)" by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. Key players i.e. Biogen Inc., Novartis International AG, Roche Holding AG and Cytokinetics, Inc are being profiled along with their respective financials and growth strategies.

Table of Contents

1. Market Overview

  • 1.1 Introduction
  • 1.2 Classification
  • 1.3 Causes & Symptoms
  • 1.4 Diagnosis
  • 1.5 Treatment

2. Global Spinal Muscular Atrophy Market

  • 2.1 Global Spinal Muscular Atrophy Market Value Forecast
  • 2.2 Global AVXS-101 Gene Therapy Value Forecast
  • 2.3 Global AVXS-101 Gene Therapy Value Forecast by Region
  • 2.4 Global SRK-015 Drug Value Forecast
  • 2.5 Global SRK-015 Drug Value Forecast by Region
  • 2.6 Global Spinal Muscular Atrophy Incidence by Region
  • 2.7 Global Spinal Muscular Atrophy Prevalence by Region

3. Regional Spinal Muscular Atrophy Market

  • 3.1 The U.S. AVXS-101 Gene Therapy Value Forecast
  • 3.2 The U.S. AVXS-101 Gene Therapy Value Forecast by Disease Type
    • 3.2.1 The U.S. AVXS-101 Gene Therapy Value Forecast by Type I
    • 3.2.2 The U.S. AVXS-101 Gene Therapy Value Forecast by Type II
  • 3.3 The U.S. SRK-015 Drug Value Forecast
  • 3.4 The U.S. SRK-015 Drug Value Forecast by Disease Type
    • 3.4.1 The U.S. SRK-015 Drug Value Forecast by Type I
    • 3.4.2 The U.S. SRK-015 Drug Value Forecast by Type III
  • 3.5 EU AVXS-101 Gene Therapy Value Forecast
  • 3.6 EU AVXS-101 Gene Therapy Value Forecast by Disease Type
    • 3.6.1 EU AVXS-101 Gene Therapy Value Forecast by Type I
    • 3.6.2 EU AVXS-101 Gene Therapy Value Forecast by Type III
  • 3.7 EU SRK-015 Drug Value Forecast
  • 3.8 EU SRK-015 Drug Value Forecast by Disease Type
    • 3.8.1 EU SRK-015 Drug Value Forecast by Type I
    • 3.8.2 EU SRK-015 Drug Value Forecast by Type III

4. Market Dynamics

  • 4.1 Growth Drivers
    • 4.1.1 Rising Pharmaceuticals Research and Development (R&D) Expenditures
    • 4.1.2 Increasing Personal Healthcare Expenditure
    • 4.1.3 Accelerating Economic Growth
    • 4.1.4 Growing Spinal Muscular Atrophy Occurrence
  • 4.2 Key Trends and Developments
    • 4.2.1 Progressing Drug Pipeline
    • 4.2.2 High Preference for Gene Therapy
  • 4.3 Challenges
    • 4.3.1 Lethargic Drug Approval Process
    • 4.3.2 Associated Business Risk

5. Competitive Landscape

  • 5.1 Global Spinal Muscular Atrophy Market
    • 5.1.1 Key Players - Revenue Comparison
    • 5.1.2 Key Players - Drug Features Comparison
    • 5.1.3 Key Players - Market Cap Comparison

6. Company Profiles

  • 6.1 Biogen Inc.
    • 6.1.1 Business Overview
    • 6.1.2 Financial Overview
    • 6.1.3 Business Strategies
  • 6.2 Novartis International AG
    • 6.2.1 Business Overview
    • 6.2.2 Financial Overview
    • 6.2.3 Business Strategies
  • 6.3 Roche Holding AG
    • 6.3.1 Business Overview
    • 6.3.2 Financial Overview
    • 6.3.3 Business Strategies
  • 6.4 Cytokinetics, Inc
  • 6.4.1 Business Overview
    • 6.4.2 Financial Overview
    • 6.4.3 Business Strategies

List of Figures

  • List of Figures
  • Global Spinal Muscular Atrophy Market Value Forecast (2018-2023)
  • Global AVXS-101 Gene Therapy Market Forecast (2019-2023)
  • Global AVXS-101 Gene Therapy Value Forecast by Region (2019-2023)
  • Global SRK-015 Drug Value Forecast (2022-2026)
  • Global SRK-015 Drug Value Forecast by Region (2022-2026)
  • Global Spinal Muscular Atrophy Incidence by Region (2018)
  • Global Spinal Muscular Atrophy Prevalence by Region (2018)
  • The U.S. AVXS-101 Gene Therapy Value Forecast (2019-2023)
  • The U.S. AVXS-101 Gene Therapy Value Forecast by Disease Type (2019-2023)
  • The U.S. AVXS-101 Gene Therapy Value Forecast by Type I (2019-2023)
  • The U.S. AVXS-101 Gene Therapy Value Forecast by Type II (2020-2024)
  • The U.S. SRK-015 Drug Value Forecast (2022-2026)
  • The U.S. SRK-015 Drug Value Forecast by Disease Type (2022-2026)
  • The U.S. SRK-015 Drug Value Forecast by Type I (2022-2026)
  • The U.S. SRK-015 Drug Value Forecast by Type III (2022-2026)
  • EU AVXS-101 Gene Therapy Value Forecast (2020-2024)
  • EU AVXS-101 Gene Therapy Value Forecast by Disease Type (2020-2024)
  • EU AVXS-101 Gene Therapy Value Forecast by Type I (2020-2024)
  • EU AVXS-101 Gene Therapy Value Forecast by Type III (2021-2025)
  • EU SRK-015 Drug Value Forecast (2023-2027)
  • EU SRK-015 Drug Value Forecast by Disease Type (2023-2027)
  • EU SRK-015 Drug Value Forecast by Type I (2023-2027)
  • EU SRK-015 Drug Value Forecast by Type III (2023-2027)
  • Global Pharmaceuticals Research and Development (R&D) Expenditures (2014-2018)
  • Global HealthCare Expenditure Per Capita (2014-2018)
  • Global Gross Domestic Product (GDP) per Capita (2014-2018)
  • Spinal Muscular Atrophy Drugs Approval Procedure
  • Key Players - Market Cap Comparison (2019)
  • Biogen Revenues by Business Segments (2018)
  • Biogen Revenues and Net Income (2014-2018)
  • Biogen R&D Expenditures (2015-2017)
  • Novartis Net Sales by Business Segments (2018)
  • Novartis Net Sales and Net Income (2014-2018)
  • Roche Sales by Business Segments (2018)
  • Roche Sales and Net Income (2014-2018)
  • Cytokinetics Revenues and Net Income (Loss) (2013-2017)
  • Cytokinetics R&D Expenditures (2015-2017)

List of Tables

  • Spinal Muscular Atrophy Drugs under Development (2018)
  • Key Players - Revenue Comparison (2018)
  • Key Players - Drug Features Comparison (2018)
  • Cytokinetics Product Pipeline (2019)
  • Cytokinetics Partnership Renewal Agreements (2018)